Dosing & Uses
Bladder Cancer
Pending FDA approval for use in combination with Bacillus Calmette-Guerin (BCG) for treatment of BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without Ta or T1 disease
Pharmacology
Mechanism of Action
Fusion protein complex composed of mutated form of cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity
Upon administration, superagonist IL-15:interleukin-15 receptor alphaSu/Fc fusion complex N-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T cells
